Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Integrated analysis of daclizumab HYP pharmacokinetics from three phase 1 studies
Visualizing Non-Gaussian Diffusion: Clinical Application of q-Space Imaging and Diffusional Kurtosis Imaging of the Brain and Spine.
In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects.
Stopping Disease Modifying Therapy in Progressive Multiple Sclerosis - A Prospective Study
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
Genmab Announces Ofatumumab Development Plans in RRMS and NMO
Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.
The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.
Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.
TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
Assessment of Disease Activity in Multiple Sclerosis Phenotypes with Combined Gadolinium- and Superparamagnetic Iron Oxide-enhanced MR Imaging.
ALSUntangled No. 8: Low dose naltrexone for ALS.
Change in the clinical development program for laquinimod
Immunomodulatory drugs (natalizumab), worsening of multiple sclerosis, rebound effect and similitude.
Multiple sclerosis: an immune or neurodegenerative disorder?
Clinical profile of malay children with optic neuritis.
Power estimation for non-standardized multisite studies.
GEMSP: A New Therapeutic Approach to Multiple Sclerosis.
Cortical demyelination and diffuse white matter injury in multiple sclerosis.
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
Regulation of prefrontal cortex myelination by the microbiota.
Current and future disease-modifying therapies in multiple sclerosis.
Rituximab Use in Pediatric Central Demyelinating Disease.

Pages